AGTC Boosts AAV Manufacturing Productivity With Herpes Simplex Virus

By using the herpes simplex virus (HSV) as a helper for its adeno-associated viral (AAV) platform UF startup and UF Innovate | Sid Martin Biotech graduate Applied Genetic Technologies Corporation (AGTC) created AAVs that are more robust, purer and lower cost than any of the other methods.

Its gene therapy program for X-linked retinitis pigmentosa (XLRP) is a case in point. By using its herpes-assisted vector expansion (HAVE) methodology, “we are now achieving finished product specifications that demonstrate nearly 90% full capsids with extremely low residuals, many of which fall below the level of detection, resulting in purity levels exceeding 97%,” said Dave Knop, Ph.D., head of process development at AGTC. “This is in addition to yields that are more than 10-fold higher than what we achieved in our Phase I/II manufacturing campaigns.” 

AGTC is a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases.

Learn more about AGTC Boosts AAV Manufacturing Productivity With Herpes Simplex Virus.